High Stakes Hemostasis: Describing Risks of Triple Antithrombotic Therapy in Patients on Temporary Mechanical Circulatory Support

Document Type

Conference Proceeding

Publication Date

6-2-2026

Publication Title

Am J Hematol

Keywords

Hematology

Abstract

Background: Dual antiplatelet therapy (DAPT) is indicated in patients undergoing percutaneous coronary intervention with drug eluting stent placement. The recommended duration of DAPT is 12 months, however factors including antiplatelet agent and risk of bleeding may necessitate an individualized duration. This population may present with cardiogenic shock and require temporary mechanical circulatory support (tMCS) that traditionally requires anticoagulation for circuit patency and poses a risk for bleeding. There is limited data on the risk factors associated with bleeding in tMCS populations receiving DAPT and therapeutic anticoagulation. This study aims to characterize risk factors associated with bleeding events in patients on tMCS receiving triple antithrombotic therapy (DAPT + anticoagulation). Objectives: The primary endpoint is to determine independent risk factors for bleeding, classified as ≥ 3a bleeding events using the Bleeding Academic Research Consortium (BARC) definition, in patients on tMCS receiving triple antithrombotic therapy. Secondary endpoints include analyzing trends in time to bleeding events and incidence of thrombotic events. Methods: This is a retrospective, registry-driven data analysis to evaluate adult patients (> 18 years old) on triple antithrombotic therapy while receiving tMCS. The registry consists of patients who received tMCS support at a high-volume, tertiary care, academic referral center. Risk factors pertaining to the patient, antithrombotic therapies, and tMCS device characteristics will be assessed using grouped comparisons and multivariable logistic regression. Results: In progress. Conclusion: In progress.

Volume

101

First Page

2

Find It @ Sladen

Share

COinS